Immunomodulatory therapy for Vogt-Koyanagi-Harada patients as first-line therapy.
about
Vogt-Koyanagi-Harada disease: review of a rare autoimmune disease targeting antigens of melanocytesVogt-Koyanagi-Harada syndrome - current perspectives.Rituximab in refractory Vogt-Koyanagi-Harada disease.Unilateral Vogt-Koyanagi-Harada Disease: A Clinical Case Report.Vogt-Koyanagi-Harada syndrome in children: report of a case and review of the literature.Effect of the duration of immunomodulatory therapy on the clinical features of recurrent episodes in Vogt--Koyanagi--Harada disease.Clinical Outcomes of Patients with Vogt-Koyanagi-Harada Disease Over 12 Years at a Tertiary Center.Reappraisal of the management of Vogt-Koyanagi-Harada disease: sunset glow fundus is no more a fatality.Outcomes of Vogt-Koyanagi-Harada Disease: A Subanalysis From a Randomized Clinical Trial of Antimetabolite TherapiesClinical spectrum and management options in Vogt-Koyanagi-Harada disease.Earlier immunomodulatory treatment is associated with better visual outcomes in a subset of patients with Vogt-Koyanagi-Harada disease.Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease.Prognostic factors for clinical outcomes in patients with Vogt-Koyanagi-Harada disease treated with high-dose corticosteroids.Infliximab therapy for 2 patients with Vogt-Koyanagi-Harada syndrome.Comparison of two different combination immunosuppressive therapies in the treatment of Vogt-Koyonagi-Harada syndrome.Longitudinal observation of subretinal fibrosis in Vogt-Koyanagi-Harada disease.The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease.Vogt-Koyanagi-Harada disease: clinical and demographic characteristics of patients in a specialized eye hospital in Turkey.Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of 'sunset glow fundus' in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease.Vogt-Koyanagi-Harada DiseaseChronic Recurrent Vogt–Koyanagi–Harada Disease and Development of ‘Sunset Glow Fundus’ Predict Worse Retinal Sensitivity
P2860
Q26752297-C2D2AAF0-E201-4DBF-AEA4-FB38DAAE0E4EQ28072882-ECD560DF-7110-42A3-B683-1F24124C969FQ35571023-90BAF583-ED04-4A61-AC14-3A872E85B95DQ36291578-8E07D501-040F-4D47-88E5-40372E1F8ED1Q36925622-0FC65F81-601E-4770-83C0-96F04D55B49EQ37830790-F957ACA7-133D-43F3-953A-60CDC4AEE5F8Q38591885-7E534D2D-47B6-493C-98A4-00273215FE64Q39008824-C33CC1FE-E031-4D17-84D3-0BD30D2296E1Q40703622-6EA11EE2-F8CB-4715-83FF-8AEC07BE8200Q41405377-7AD0AC11-D094-4D60-B5AB-2884E593FD17Q41614992-E4C9340F-8769-43AD-A511-261F41E8B5E7Q43060159-446506CD-AAE7-4FAE-B6D7-84D37F7E01BEQ43469154-40172A38-A68F-492A-AB60-DF2E093114BEQ46419310-B93D9777-2C9B-49EE-B8B7-61E6D9338643Q46846443-7C922644-58E1-4C7C-B172-7B3F939F1B8AQ48241790-E96ED4B6-6FE9-4973-94A2-AA2863A41CB4Q50490823-17B4A177-8CBE-4E96-AA8D-561234906582Q51177631-193BBDD3-F6D2-416E-94BC-408B00D469A9Q53033802-94971030-1E1F-438D-8AC0-8A276090D8C8Q55982733-C6DE0883-4177-4E57-AFA2-70DE7C848F12Q57584157-4069A0CF-F485-4ABC-B158-45CDDFC19BBB
P2860
Immunomodulatory therapy for Vogt-Koyanagi-Harada patients as first-line therapy.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Immunomodulatory therapy for Vogt-Koyanagi-Harada patients as first-line therapy.
@en
Immunomodulatory therapy for Vogt-Koyanagi-Harada patients as first-line therapy.
@nl
type
label
Immunomodulatory therapy for Vogt-Koyanagi-Harada patients as first-line therapy.
@en
Immunomodulatory therapy for Vogt-Koyanagi-Harada patients as first-line therapy.
@nl
prefLabel
Immunomodulatory therapy for Vogt-Koyanagi-Harada patients as first-line therapy.
@en
Immunomodulatory therapy for Vogt-Koyanagi-Harada patients as first-line therapy.
@nl
P2093
P2860
P1476
Immunomodulatory therapy for Vogt-Koyanagi-Harada patients as first-line therapy.
@en
P2093
P2860
P356
10.1080/09273940500536766
P577
2006-04-01T00:00:00Z